The Role of Treatment in Hepatitis Elimination

ANNETTE GAUDINO, HIV/HCV PROJECT CO-DIRECTOR
NATIONAL HEPATITIS TECHNICAL ASSISTANCE MEETING
NOVEMBER 28-30, 2017
WASHINGTON DC
Treatment for Elimination: Opportunities and Challenges

The moral cost of high drug prices

- $24.5B to cure all 71M living with chronic HCV worldwide with generics vs $66B in revenue from DAAs
- All HCV related deaths are preventable

Leverage the newly competitive landscape

- Correct the myth of the $1000 pill – only state prisons pay this price
- Duopoly: Merck and Janssen exit
- Formularies: the power of no
Treatment for Elimination: Opportunities and Challenges

Help community communicate with elected officials
  Collaborate with community to set targets
  Provide data by legislative district: people with hepatitis are constituents

Remove hidden barriers to universal treatment
  End Medicaid prior authorization denials
  NYS AI CEI course *Hepatitis C Prior Authorization: Tricks of the Trade*
  ceitraining.org
Treatment for Elimination: Opportunities and Challenges

Treatment outside primary care settings requires federal/state coordination
Reimbursement for pharmacy, OST, CBO based care coordination
State prisons included in best price: de-incentivizes volume discounts

National Hepatitis Corrections Network
www.hcvinprison.org

Minnesota Multistate Contracting Alliance for Pharmacy (MMCAP)
www.mmd.admin.state.mn.us/mmcap/
mn.multistate@state.mn.us
Treatment for Elimination: Opportunities and Challenges

Treatment as Prevention

Take the care continuum beyond cure: life long drug user health, HCC

Target networks for Ab screening/RNA testing through “buddy system” and incentives

If you’re not seeing reinfection, you’re not treating the right people

Treatment Action Group
www.treatmentactiongroup.org
annette.gaudino@treatmentactiongroup.org